MBX Biosciences, Inc. (MBX)

MBX Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	49.35	30.52	24.21
Short-Term Investments	212.8	50.15	18.25
Cash & Short-Term Investments	262.15	80.68	42.46
Cash Growth	224.94%	90.00%	-
Other Receivables	0.68	0.21	0.14
Receivables	0.68	0.21	0.14
Prepaid Expenses	3.65	2.45	1.52
Other Current Assets	0.8	0.13	0.08
Total Current Assets	267.29	83.47	44.21
Property, Plant & Equipment	1.2	0.67	0.84
Other Long-Term Assets	0.05	0.05	0.04
Total Assets	268.54	84.18	45.1
Accounts Payable	5.34	1.39	0.98
Accrued Expenses	5.55	2.38	2.32
Current Portion of Leases	0.17	0.15	0.14
Total Current Liabilities	11.05	3.93	3.43
Long-Term Leases	-	0.17	0.32
Other Long-Term Liabilities	0.04	0.19	0.07
Total Liabilities	11.09	4.29	3.82
Common Stock	0.01	0	0
Additional Paid-In Capital	394.89	3.05	0.41
Retained Earnings	-137.51	-75.58	-43.02
Comprehensive Income & Other	0.06	0.06	0
Total Common Equity	257.44	-72.47	-42.61
Shareholders' Equity	257.44	79.89	41.27
Total Liabilities & Equity	268.54	84.18	45.1
Total Debt	0.17	0.32	0.46
Net Cash (Debt)	261.98	80.35	42
Net Cash Growth	226.04%	91.31%	-
Net Cash Per Share	24.62	78.87	62.97
Filing Date Shares Outstanding	33.42	1.26	0.67
Total Common Shares Outstanding	33.42	1.26	0.67
Working Capital	256.24	79.54	40.78
Book Value Per Share	7.70	-57.65	-63.87
Tangible Book Value	257.44	-72.47	-42.61
Tangible Book Value Per Share	7.70	-57.65	-63.87
Machinery	1.11	0.24	0.23
Construction In Progress	-	0	-
Leasehold Improvements	0.39	0.37	0.35

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q